Related Experiment Video

Updated: Jun 5, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

Response to combined molecular targeting: defining the role of P-STAT3

Ann Marie Egloff1, Jennifer R Grandis

  • 1Department of Otolaryngology and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 27, 2011
PubMed

Insights

Src family kinase (SFK) inhibitors show promise for solid tumors. However, resistance can occur via STAT3 phosphorylation independent of EGFR. Tumor STAT3 phosphorylation may predict treatment response to SFK inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Src family kinases (SFKs) are targets in solid tumor treatment.
  • Resistance to SFK-targeting agents is a clinical challenge.
  • Epidermal growth factor receptor (EGFR)-independent STAT3 phosphorylation is a known resistance mechanism.

Purpose of the Study:

  • To investigate the role of STAT3 phosphorylation in resistance to SFK inhibitors.
  • To evaluate tumor P-STAT3 levels as a predictive biomarker for SFK-targeted therapies.

Main Methods:

  • Analysis of tumor samples from patients treated with SFK inhibitors.
  • Assessment of phosphorylated STAT3 (P-STAT3) levels.
  • Correlation of P-STAT3 levels with treatment response and EGFR status.

Main Results:

  • Elevated tumor P-STAT3 levels were observed.
  • EGFR-independent P-STAT3 activation was confirmed as a resistance mechanism.
  • Higher P-STAT3 levels correlated with reduced efficacy of SFK-targeting agents.

Conclusions:

  • Tumor STAT3 phosphorylation is a key mechanism of resistance to SFK inhibitors.
  • P-STAT3 levels may serve as a predictive biomarker for EGFR- and SFK-targeted antitumor treatment efficacy.
  • Monitoring P-STAT3 could guide therapeutic strategies in solid malignancies.

More Related Videos

Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis10:22

Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis

Published on: August 15, 2013

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...